列沃西曼丹和心房动:随机对照试验的元分析
Huan Wan1, Jihua Feng1, Pan Ji1
1Department of Emergency Medicine,The Second Affiliated Hospital of Guangxi Medical University, Nanning - Guangxi China.
Arquivos brasileiros de cardiologia
|August 21, 2024
概括
莱沃西门丹在非术后环境中增加了心房动 (AF) 的风险,但在心脏手术后有效地预防AF. 剂量策略可能会影响结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 心房动 (AF) 是与使用levosimendan相关的常见并发症.
- 关于levosimendan对非术后和术后AF的差异性影响存在不确定性.
研究的目的:
- 评估levosimendan对非术后和术后心房动 (AF) 的影响.
- 进行随机对照试验 (RCT) 的元分析,以评估levosimendan关于AF发病率的疗效和安全性.
主要方法:
- 在PubMed,Embase和Cochrane图书馆进行了系统的文献搜索.
- 确定了随机对照试验 (RCT),将levosimendan与安慰剂或其他治疗方法进行比较.
- 随机效应模型被用于分析报告的AF事件数据.
主要成果:
- 包括29项试验,6550名参与者,分析了非术后 (11项试验) 和术后 (18项试验) AF.
- 在非术后组中,levosimendan显著增加了AF风险 (OR,1.62),但在术后组中降低了AF发病率 (OR,0.65).
- 与心脏手术前使用相比,心脏手术后使用显示出更显著的AF减少 (OR,0.53);大剂量 (≥12μg/kg) 增加了AF风险 (OR,1.44).
结论:
- 利沃西门丹与非手术后的AF发病率较高有关.
- 使用levosimendan是有效的预防手术后的AF,特别是在心脏手术后.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
940
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
940
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
800
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
800
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
01:26Heart Failure Drugs: Inotropic Agents
547
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
547